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Abstract
Background: Cystic fibrosis (CF) has many effects on the gastrointestinal tract and a common problem in this disease is poor
nutrition. In the CF mouse there is an innate immune response with a large influx of mast cells into the muscularis externa of
the small intestine and gastrointestinal dysmotility. The aim of this study was to evaluate the potential role of mast cells in
gastrointestinal dysmotility using the CF mouse (Cftr
tm1UNC, Cftr knockout).
Methodology: Wild type (WT) and CF mice were treated for 3 weeks with mast cell stabilizing drugs (ketotifen, cromolyn,
doxantrazole) or were treated acutely with a mast cell activator (compound 48/80). Gastrointestinal transit was measured
using gavage of a fluorescent tracer.
Results: In CF mice gastric emptying at 20 min post-gavage did not differ from WT, but was significantly less than in WT at
90 min post-gavage. Gastric emptying was significantly increased in WT mice by doxantrazole, but none of the mast cell
stabilizers had any significant effect on gastric emptying in CF mice. Mast cell activation significantly enhanced gastric
emptying in WT mice but not in CF mice. Small intestinal transit was significantly less in CF mice as compared to WT. Of the
mast cell stabilizers, only doxantrazole significantly affected small intestinal transit in WT mice and none had any effect in CF
mice. Mast cell activation resulted in a small but significant increase in small intestinal transit in CF mice but not WT mice.
Conclusions: The results indicate that mast cells are not involved in gastrointestinal dysmotility but their activation can
stimulate small intestinal transit in cystic fibrosis.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disease
caused by mutations in the CFTR (cystic fibrosis transmembrane
conductance regulator) gene. CFTR is a cAMP-regulated chloride
channel that in the intestine is mainly expressed in the apical
plasma membrane of crypt cells. In the absence of CFTR, fluid
secretion into the intestinal lumen is of low volume and is deficient
in bicarbonate, which impairs neutralization of gastric acid. The
poorly-hydrated acidic luminal environment is believed to cause
accumulation of mucus, which fosters bacterial overgrowth of the
CF small intestine [1].
Hallmarks of CF in affected epithelial organs, including the
intestine, are accumulation of excessive mucus, microbial
infection, and inflammation. Inflammation is known to affect
gastrointestinal motility patterns [2,3]. Inflammation of the human
CF intestine has been reported [4–6] but, because such studies use
indirect measures or require invasive methods, there is not much
detailed information. Inflammation of the CF intestine may be a
response to bacterial overgrowth, which is reported to occur in up
to half of CF patients [7,8]. Consistent with intestinal inflamma-
tion, gastrointestinal dysmotility has been reported to be frequent
in CF patients [8–14].
The Cftr knockout mouse (Cftr
tm1UNC, CF mouse) small intestine
exhibits many of the same changes that occur in CF patients,
including excessive mucus accumulation, impaired intestinal
transit, bacterial overgrowth, and an inflammatory response
[15,16]. Inflammation in the CF mouse intestine has character-
istics of an innate response that includes an influx of mast cells,
mainly into the muscularis externa tissue [17].
Mast cells have been implicated in various conditions where
gastrointestinal motility is altered [18]. Mast cells can stimulate
motility during acute intestinal infection with pathogenic bacteria
[19]. Mast cells produce histamine and serotonin, both of which
can stimulate enteric smooth muscle contraction [20]. In other
conditions mast cells are associated with impaired motility, often
due to deleterious effects of mast cell proteases on the interstitial
cells of Cajal [21] or on the enteric nervous system [2,18,22–24].
For example, using in vitro co-cultures of enteric nerves with
peritoneal mast cells, it was shown that mast cells damage the
nerves [25]. Inclusion of the mast cell stabilizer doxantrazole in the
culture system prevented nerve cell damage demonstrating the
importance of mast cell activity.
Because the CF mouse small intestine has impaired transit and a
dramatic increase in mast cells in the muscularis, we hypothesized
that the mast cells may play a role in slowed gastrointestinal transit
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All animal procedures were approved by the Institutional
Animal Care and Use Committee.
Materials
Unless otherwise specified, all chemicals were obtained from
Sigma-Aldrich (St. Louis, MO, USA).
Animals
Cftr(+/2) mice (Cftr
tm1UNC) were originally obtained from the
Jackson Laboratory (Bar Harbor, ME, USA). As previously
described, the mice were bred to be congenic on the C57BL/6J
background [26]. Cftr(+/2) mice were bred to obtain wild type
(WT) [Cftr(+/+)] and CF [Cftr(2/2)] mice. Cftr(+/2) mice, which
are phenotypically indistinguishable from WT, were used
occasionally as WT. Mice of both sexes were used between 6–
7 weeks of age and no gender-related differences in the measured
parameters were observed. To prevent lethal intestinal obstruc-
tion, all mice were fed ad libitum a complete elemental liquid diet
(Peptamen; Nestle, Deerfield, IL, USA) [27]. The following mast
cell stabilizers were administered at doses derived from published
work, by addition to the liquid diet for three weeks: ketotifen
(1 mg/kg-day) [28], cromolyn (10 mg/kg-day) [29,30]; doxantra-
zole (10 mg/kg-day) [31]. The mast cell stimulator compound 48/
80 was administered acutely by i.p. injection of 0.75 mg/kg body
weight [32] 30 min before gavage of the motility tracer (see
below).
Measurement of gastric emptying and gastrointestinal
transit
Gastric emptying and transit were measured as previously
described [15]. Briefly, mice were fasted overnight with free
access to water. In the morning between 8–9 AM, mice were
gavaged with 100 ml 25 mg/ml rhodamine dextran
(MW=70000). After 20 min, the mice were killed and the
gastrointestinal tract was divided into stomach, 10 equal
segments of small intestine, and large intestine. The stomach
and intestinal segments were flushed and the concentration of
the tracer was determined fluorometrically in a Synergy HT
microplate reader (BioTek, Winooski, Vermont, USA). Gastric
emptying was calculated as the percent of tracer remaining in the
stomach relative to the total amount recovered from the stomach
and intestine. For measurement of small intestinal transit the
fluorescence data were expressed per segment relative to the
total in the intestine. For some experiments the post-gavage time
was 90 min.
Mast cell histochemistry
Tissue was fixed with 4% paraformaldehyde and paraffin
sections were prepared. Sections were stained with toluidine blue
which stains all mature mast cells [33,34] by binding to serglycin
proteoglycans in their secretory granules [35]. Slides were imaged
on a Nikon Diaphot microscope equipped with a SPOT RT-KE
digital camera (Diagnostic Instruments, Sterling Heights, MI,
USA). Mast cells were counted in images of the stained slides by an
observer unaware of the sample identities. Tissue areas were
calculated using NIH Image J software.
Statistical analysis
Statistical significance was determined by ANOVA with a post-
hoc Fisher’s least significant difference test (Systat, Chicago, IL,
USA). A P-value of ,0.05 was considered significant.
Results
The aim of this study was to test the role of mast cells in
gastrointestinal dysmotility in the CF mouse. We have previously
shown that the CF mouse has many more mast cells in the small
intestine as compared to wild type (WT) mice [17]. It was not
known if the numbers of mast cells in the CF mouse stomach also
differed, so we first examined this in wild type (WT) and CF
stomachs. Mast cells were readily observed in both WT and CF
stomach tissues (Fig. 1A and B, respectively). There was no
significant difference in the numbers of mucosal or connective
tissue/muscularis externa mast cells comparing WT and CF
stomachs (Fig. 2). The density of mast cells we measured in the
stomach agrees well with previous reports on healthy mice [33].
Our previous work showed that in the small intestine of the CF
mouse in comparison to WT, there are 50–100 fold more mast
cells, principally in the muscularis externa [17] (Fig. 1C). In
contrast, mast cells are rare in the WT intestine, consistent with
other reports [33,36,37]. The occasional mast cells that were
observed in the WT intestine were mostly in the peritoneal space
(Fig. 1D) and none were in the muscualris externa.
To measure gastric emptying and intestinal transit, mice were
fasted overnight and in the morning they were gavaged with
rhodamine dextran, a non-absorbable tracer. Twenty or 90 min
later, the distribution of the fluorescent tracer was measured in the
stomach, small intestine, and large intestine. At 20 min post-
gavage in untreated control mice gastric emptying was somewhat
less in CF mice as compared to WT, but the difference was not
statistically significant (Fig. 3, 4). In both WT and CF mice, at
20 min post-gavage the remainder of the tracer was in the small
intestine with none in the large intestine (Fig. 3). When the post-
gavage period was extended to 90 min, WT mice showed
significant decreases of the tracer in the stomach and small
intestine, and an increase in the large intestine (Fig. 3A), as
compared to the 20 min WT data. In the CF mice at 90 min post-
gavage, there was significantly less tracer in the stomach as
compared to the 20 min CF data (Fig. 3B). In comparison to WT,
the CF mice had significantly more tracer in the stomach and
small intestine, and less in the large intestine (Fig. 3B) at 90 min
post-gavage. We chose to use 20 min post-gavage for the
remainder of the experiments. At this time point, the distribution
of tracer in the gastrointestinal tract would allow detection of
changes in gastric emptying or improved small intestinal transit
comparing WT to CF mice after treatment with the mast cell
active agents.
To assess the effects of mast cells on gastric emptying and small
intestinal transit we treated mice with various mast cell stabilizers.
There are several drugs known to stabilize mast cells, and there is
some specificity as to whether mucosal or connective tissue mast
cells are affected. Because of the uncertainty of the phenotype of
mast cells in the CF intestine (see Discussion) and which drugs
would act on which type of mast cells, we used three different
drugs.
The first drug used was ketotifen, which stabilizes connective
tissue mast cells and is also a histamine H1 receptor antagonist.
Ketotifen treatment for three weeks had no effect on gastric
emptying in either WT or CF mice (Fig. 4). Ketotifen also did not
affect the distribution of the tracer along the small intestine (small
intestinal transit) in either WT or CF mice (Fig. 5C and D).
Mast Cells in GI Transit in CF
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mast cells. Cromolyn was without effect on gastric emptying in
WT or CF mice (Fig. 4). In WT mice treated with cromolyn, the
tracer was more evenly distributed along the length of the small
intestine as compared to control WT (Fig. 5E). Cromolyn had no
effect on the distribution of tracer in the CF mouse small intestine
(Fig. 5F).
Doxantrazole, a drug that targets both connective tissue and
mucosal mast cells, was the third one used. There was a significant
increase in gastric emptying in WT mice treated with doxantrazole
but not in CF mice (Fig. 4). Doxantrazole caused a slight but
significant change in the distribution of the tracer in the small
intestine of WT mice (Fig. 5G) but the effect was not significant in
CF mice (Fig. 5H).
We next tested the effect of stimulation of mast cells by
compound 48/80, administered as an i.p. injection 30 min
before gavage of the motility tracer. As compared to control,
compound 48/80 significantly increased gastric emptying in WT
mice (Fig. 4). In CF mice compound 48/80 had a small effect on
gastric emptying as compared to control CF mice, but the
difference did not reach the level of statistical significance
(P=0.08) (Fig. 4). In WT mice treated with compound 48/80,
the distribution of the fluorescent tracer in the small intestine was
more even than in control WT mice, but the effect was not
statistically significant (Fig. 5I). In contrast, mast cell activation
caused a significant change in the distribution of the tracer in the
C Fm o u s es m a l li n t e s t i n e( F i g .5 J ) .W h e r e a st h e r ew a sl i t t l et r a c e r
past the second segment of the small intestine in control CF
mice, in the compound 48/80 treated CF mice there was
significantly less tracer in the first segment and more in the third
segment.
Discussion
In this study we investigated the potential role of mast cells in
gastrointestinal dysmotility in the CF mouse model of cystic
fibrosis. Whereas healthy WT mice have very few mast cells in the
small intestine [33,37], in contrast to humans where intestinal mast
cells are common, there is a dramatic elevation of mast cells in the
CF mouse small intestine. This influx of mast cells in the CF small
intestine is likely in response to the bacterial overgrowth that
occurs. The bacteria that overgrow the CF small intestine are
opportunistic and they colonize the mucus that accumulates in the
CF intestine [1,16]. When bacterial overgrowth in CF mice is
Figure 1. Histochemistry for mast cells in WT and CF mouse stomach and small intestine. Sections were stained with toluidine blue and
mast cells identified by their metachromatic staining. (A) Wild type stomach; (B) CF Stomach; (C) Wild type small intestine; (D) CF small intestine.
Arrowheads indicate mast cells. Representative from 7 WT and 7 CF stomachs.
doi:10.1371/journal.pone.0004283.g001
Figure 2. Quantitation of mast cells in stomach of WT and CF
mice. There were no significant differences in the numbers of mast
cells per unit area in the CF stomach as compared to WT, in either
mucosa or connective tissue (CT, which included the muscularis
externa). Data are means 6 SEM. (n=7 WT, 7 CF stomachs)
doi:10.1371/journal.pone.0004283.g002
Mast Cells in GI Transit in CF
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that of control WT mice [16].
Because mast cells have been shown to affect gastrointestinal
motility in various conditions, including in the bacterially infected
intestine, we hypothesized that mast cells would play an important
role in dysmotility in the CF mouse gastrointestinal tract.
However, using a variety of mast cell stabilizing drugs, there was
no significant improvement in gastric emptying or small intestinal
transit in the CF mouse. There was a small but significant increase
in small intestinal transit after activation of mast cells with
compound 48/80 in CF mice but not in WT mice. This
demonstrates that the increased numbers of mast cells in the CF
intestine can affect intestinal motility, but their presence alone
does not underlie the dysmotility of the CF gut.
Mast cells display tremendous diversity depending on their
tissue site and the nature of the inflammation to which they are
responding [38,39]. Two main ways to classify mast cells are
based on their tissue localization and on their enzymatic profile.
By an earlier Affymetrix GeneChip analysis, all of the 11 mast
cell protease genes on the array were called absent in the WT
mouse small intestine [17]. This is consistent with the very low
numbers of mature mast cells in the healthy mouse small
intestine. In the CF mouse intestine several mast cell protease
genes were expressed: mast cell protease 1 (Mcpt1), mast cell
Figure 3. Distribution of rhodamine dextran along the gastrointestinal tract of WT and CF mice at 20 min and 90 min post-gavage.
Overnight fasted mice were gavaged with a bolus of rhodamine dextran (see Methods). At either 20 min or 90 min post-gavage the mice were
sacrificed and the distribution of the fluorescence in the stomach (St), small intestine (SI) and large intestine (LI) was measured and expressed relative
to the total. (A) WT mice (n=28 mice 20 min post-gavage, n=8 mice 90 min post-gavage); (B) CF mice (n=14 mice 20 min post-gavage, n=7 mice
90 min post-gavage). Data are means 6 SEM. (*) P,0.05 comparing 20 min vs 90 min data for the same organ and genotype of mice. (+) P,0.05
comparing CF vs WT for the same organ and post-gavage time.
doi:10.1371/journal.pone.0004283.g003
Figure 4. Gastric emptying in WT and CF mice and effect of mast cell agents. Overnight fasted mice were gavaged with a bolus of
rhodamine dextran (see Methods). At 20 min post-gavage the mice were sacrificed and the distribution of the fluorescence in the stomach and small
intestine was measured. Gastric emptying is expressed as fraction of total fluorescence which has exited the stomach in the 20 min post-gavage
period. Con=control (n=28 WT, n=14 CF); Ket=ketotifen, 3 week treatment (n=10 WT, n=6 CF); Crom=cromolyn 3 week treatment (n=11 WT,
n=7 CF); Dox=doxantrazole 3 week treatment (n=5 WT , n=8 CF); 48/80=compound 48/80 acute i.p. injection (n=4 WT, n=6 CF). Data are means
6 SEM. (*) P,0.05 vs Control of the same genotype. Data for the control WT and CF mice include values from previous work [1].
doi:10.1371/journal.pone.0004283.g004
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PLoS ONE | www.plosone.org 4 January 2009 | Volume 4 | Issue 1 | e4283Figure 5. Transit of rhodamine dextran in the small intestine and effect of mast cell agents. Overnight fasted mice were gavaged with a
bolus of rhodamine dextran (see Methods). At 20 min post-gavage the mice were sacrificed and the distribution of the fluorescence in 10 segments
(proximal to distal) of the small intestine was measured and expressed relative to the total fluorescence. (A) WT Control (n=28); (B) CF Control
(n=14); (C) Ketotifen, 3 week treatment of WT (n=10); (D) Ketotifen, 3 week treatment of CF (n=6); (E) Cromolyn, 3 week treatment of WT (n=11);
(F) Cromolyn, 3 week treatment of CF (n=7); (G) Doxantrazole, 3 week treatment of WT (n=5); (H) Doxantrazole, 3 week treatment of CF (n=8); (I)
Compound 48/80, acute i.p. injection of WT (n=4); (J) Compound 48/80, acute i.p. injection of CF (n=6). Data are means 6 SEM. (*) P,0.05 vs
control, same genotype and same intestinal segment; (+) P,0.05 CF vs WT, same segment and treatment group. Data for the control WT and CF mice
include values from previous work [1].
doi:10.1371/journal.pone.0004283.g005
Mast Cells in GI Transit in CF
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Mcp10), mast cell carboxypeptidase A3 (Cpa3), and mast cell
protease-like (Mcptl) [17]. There was unmeasurable expression of
the other mast cell markers on the arrays of the CF samples
[mast cell protease 4 (Mcpt4), chymase 1 (Cma1,a l s oc a l l e d
Mcpt5), trypase b2( Tpsb2,a l s oc a l l e dMcpt6), and tryptase a/b1
(Tpsab1,a l s oc a l l e dMcpt7)].
Based on tissue localization and protease gene expression, it is
not clear how to classify the mast cells in the CF mouse small
intestine. These mast cells are predominantly localized to the
muscularis externa layer (Fig. 1D), with occasional cells in the
submucosa [17]. This localization would classify them as
connective tissue mast cells. However, their protease expression
profile does not fit the distinct patterns of mucosal vs. connective
tissue mast cells (e.g., Mcpt1 and Mcpt2 are regarded as a mucosal
mast cell markers in mice, and Cpa3 is connective tissue mast cell
marker, but all are expressed in the CF intestine; and whereas
Cma1 is a connective tissue marker it is not expressed in the CF
intestine) [38–41].
Because of the uncertainty of how to classify the mast cells in the
CF small intestine, we used a variety of mast cell stabilizers.
However, none of the mast cell stabilizers which have activity on
the different types of mast cells had a positive effect on
gastrointestinal motility in the CF mouse.
In summary, this study shows that mast cell stabilizers were not
able to improve gastrointestinal motility in CF mice. There was a
small increase in small intestinal transit in CF mice when mast cells
were stimulated but this effect was small and transit was still much
less than in healthy WT control mice. Thus, unlike other
conditions where dysmotility occurs, mast cells are not likely to
be a useful therapeutic target to improve gastrointestinal motility
in CF.
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